{"id":13591,"date":"2025-08-19T18:12:40","date_gmt":"2025-08-19T12:42:40","guid":{"rendered":"https:\/\/www.torusdigital.com\/toruscope\/?p=13591"},"modified":"2025-11-10T12:44:11","modified_gmt":"2025-11-10T07:14:11","slug":"anondita-medicare-ipo-opens-what-investors-need-to-know","status":"publish","type":"post","link":"https:\/\/www.torusdigital.com\/toruscope\/news\/anondita-medicare-ipo-opens-what-investors-need-to-know\/","title":{"rendered":"Anondita Medicare Limited IPO Opens: Key Details Investors Shouldn\u2019t Miss"},"content":{"rendered":"

[vc_section el_id=”blog-inner-layout”][vc_row overlay_dotted=””][vc_column el_class=”blog_primary”][vc_row_inner][vc_column_inner][vc_column_text css=””]India\u2019s IPO market remains robust in August 2025, with several high-profile offerings lined up across various sectors. Riding this momentum, Anondita Medicare Limited, a manufacturer of male condoms, has opened its IPO on August 22, 2025.<\/p>\n

Here is a detailed insight into the Anondita Medicare IPO<\/a> and the industry outlook.<\/span><\/p>\n

<\/span>About Anondita Medicare Ltd.<\/b><\/span><\/h2>\n

Incorporated in March 2024, Anondita Medicare Limited is a manufacturer of male condoms with its flagship product sold under the brand name ‘COBRA’. The company’s products are available in a variety of flavours and are 100% electronically tested. Anondita Medicare’s manufacturing facility is located in Noida, Uttar Pradesh, and has an installed capacity of nearly 562 million condoms per year. The company also supplies products to government health programs and institutions.<\/span><\/p>\n

The company’s business was previously run as a sole proprietorship under the name M\/s Anondita Healthcare (formerly M\/s Healthcare Products) since 1999, before being transferred to the newly incorporated public limited company.<\/span><\/p>\n

<\/span>Anondita Medicare Ltd. IPO Details<\/b><\/span><\/h2>\n

The IPO is a book-building issue of \u20b969.50 crore, consisting entirely of a fresh issue of 0.48 crore shares.\u00a0<\/span><\/p>\n

<\/span>Important IPO Timeline<\/b><\/span><\/h2>\n\n\n\n\n\n\n\n\n\n\n
Event<\/b><\/td>\nDate<\/b><\/td>\n<\/tr>\n
IPO Open Date<\/b><\/td>\nFri, Aug 22, 2025<\/span><\/td>\n<\/tr>\n
IPO Close Date<\/b><\/td>\nTue, Aug 26, 2025<\/span><\/td>\n<\/tr>\n
Tentative Allotment<\/b><\/td>\nThu, Aug 28, 2025<\/span><\/td>\n<\/tr>\n
Initiation of Refunds<\/b><\/td>\nFri, Aug 29, 2025<\/span><\/td>\n<\/tr>\n
Credit of Shares to Demat<\/b><\/td>\nFri, Aug 29, 2025<\/span><\/td>\n<\/tr>\n
Tentative Listing Date<\/b><\/td>\nMon, Sep 1, 2025<\/span><\/td>\n<\/tr>\n
Cut-off time for UPI mandate confirmation<\/b><\/td>\n5 PM on Aug 26, 2025<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n


\n\"\"
\n<\/a><\/p>\n

<\/span>Key IPO Details<\/b><\/span><\/h2>\n\n\n\n\n\n\n\n\n\n\n\n\n
Particulars<\/b><\/td>\nDetails<\/b><\/td>\n<\/tr>\n
Face Value<\/b><\/td>\n\u20b910 per share<\/span><\/td>\n<\/tr>\n
Issue Price Band<\/b><\/td>\n\u20b9137 to \u20b9145 per share<\/span><\/td>\n<\/tr>\n
Lot Size<\/b><\/td>\n1,000 Shares<\/span><\/td>\n<\/tr>\n
Total Issue Size<\/b><\/td>\n47,93,000 shares (aggregating up to \u20b969.50 Cr)<\/span><\/td>\n<\/tr>\n
Fresh Issue<\/b><\/td>\n47,93,000 shares (aggregating up to \u20b969.50 Cr)<\/span><\/td>\n<\/tr>\n
Issue Type<\/b><\/td>\nBookbuilding IPO<\/span><\/td>\n<\/tr>\n
Listing At<\/b><\/td>\nNSE SME<\/span><\/td>\n<\/tr>\n
Shareholding Pre-Issue<\/b><\/td>\n1,32,93,618 shares<\/span><\/td>\n<\/tr>\n
Shareholding Post-Issue<\/b><\/td>\n1,80,86,618 shares<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

<\/span>Lot Size of Anondita Medicare Ltd. IPO<\/b><\/span><\/h2>\n\n\n\n\n\n\n\n\n
Application<\/b><\/td>\nLots<\/b><\/td>\nShares<\/b><\/td>\nAmount<\/b><\/td>\n<\/tr>\n
Individual investors (Retail) (Min)<\/b><\/td>\n2<\/span><\/td>\n2,000<\/span><\/td>\n\u20b92,90,000<\/span><\/td>\n<\/tr>\n
Individual investors (Retail) (Max)<\/b><\/td>\n2<\/span><\/td>\n2,000<\/span><\/td>\n\u20b92,90,000<\/span><\/td>\n<\/tr>\n
S-HNI (Min)<\/b><\/td>\n3<\/span><\/td>\n3,000<\/span><\/td>\n\u20b94,35,000<\/span><\/td>\n<\/tr>\n
S-HNI (Max)<\/b><\/td>\n6<\/span><\/td>\n6,000<\/span><\/td>\n\u20b98,70,000<\/span><\/td>\n<\/tr>\n
B-HNI (Min)<\/b><\/td>\n7<\/span><\/td>\n7,000<\/span><\/td>\n\u20b910,15,000<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

<\/span>Anondita Medicare Ltd. Financials<\/b><\/span><\/h2>\n

The Anondita Medicare IPO is valued at a market capitalisation of \u20b9262.26 crore at the upper end of the price band. The company has shown strong financial growth in recent years.<\/span><\/p>\n

<\/span>Company Financial Snapshot<\/b><\/span><\/h2>\n\n\n\n\n\n\n\n\n\n\n
Period Ended<\/b><\/td>\n31 Mar 2025<\/b><\/td>\n31 Mar 2024<\/b><\/td>\n31 Mar 2023<\/b><\/td>\n<\/tr>\n
Assets (\u20b9 Cr)<\/b><\/td>\n78.27<\/span><\/td>\n43<\/span><\/td>\n37.80<\/span><\/td>\n<\/tr>\n
Total Income (\u20b9 Cr)<\/b><\/td>\n77.13<\/span><\/td>\n47<\/span><\/td>\n36.14<\/span><\/td>\n<\/tr>\n
Profit After Tax (\u20b9 Cr)<\/b><\/td>\n16.42<\/span><\/td>\n4<\/span><\/td>\n0.35<\/span><\/td>\n<\/tr>\n
EBITDA (\u20b9 Cr)<\/b><\/td>\n25.65<\/span><\/td>\n9<\/span><\/td>\n3.58<\/span><\/td>\n<\/tr>\n
Net Worth (\u20b9 Cr)<\/b><\/td>\n37.87<\/span><\/td>\n11<\/span><\/td>\n8.69<\/span><\/td>\n<\/tr>\n
Reserves and Surplus (\u20b9 Cr)<\/b><\/td>\n24.58<\/span><\/td>\n10.39<\/span><\/td>\n6.55<\/span><\/td>\n<\/tr>\n
Total Borrowing (\u20b9 Cr)<\/b><\/td>\n27.39<\/span><\/td>\n24.01<\/span><\/td>\n22.66<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

<\/span>Anondita Medicare Ltd.: Industry Outlook<\/b><\/span><\/h2>\n

The personal healthcare and contraceptives market in India is experiencing steady growth, driven by increasing awareness, a rising young population, and government initiatives. Anondita Medicare’s focus on quality products and its established presence, including supplying government programs, positions it well to benefit from these trends.<\/span><\/p>\n

However, investors should be aware of the competitive landscape, which includes both domestic and international players, and potential changes in government policies and public health programs that could affect its business.<\/span><\/p>\n

<\/span>Use of IPO Proceeds<\/b><\/span><\/h2>\n

The net proceeds from the fresh issue will be utilised for:<\/span><\/p>\n\n\n\n\n\n\n
S.No.<\/b><\/td>\nPurpose of the Issue<\/b><\/td>\nExpected Amount<\/b><\/p>\n

\u00a0(\u20b9 Cr)<\/b><\/td>\n<\/tr>\n

1<\/span><\/td>\nFinancing capital expenditure for the purchase of equipment and machinery<\/span><\/td>\n60<\/span><\/td>\n<\/tr>\n
2<\/span><\/td>\nFinancing the working capital needs<\/span><\/td>\n350<\/span><\/td>\n<\/tr>\n
3<\/span><\/td>\nFunding for unidentified acquisitions and general corporate purposes<\/span><\/td>\n—<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

<\/span>Anondita Medicare IPO Peer Comparison<\/b><\/span><\/h2>\n

The healthcare sector<\/a> is highly competitive. Anondita Medicare Limited’s key listed peers include Dr. Lal PathLabs and Thyrocare Technologies. While these companies operate in the same industry, they have different service offerings, market coverage, and growth strategies. When evaluating the Anondita Medicare IPO, investors should consider its strong service portfolio, focus on expansion, and commitment to quality healthcare services relative to its peers.<\/span><\/p>\n

<\/span>Conclusion<\/b><\/span><\/h2>\n

Anondita Medicare Ltd IPO offers investors exposure to the growing personal healthcare sector, particularly the condom manufacturing segment. The company’s solid financial performance and strategic use of IPO<\/a> proceeds for expansion and operational funding suggest a positive long-term outlook.<\/span><\/p>\n

As an SME IPO, it is a high-risk, high-reward investment. Investors should carefully assess their risk profile before considering an investment. The IPO may appeal to those with a long-term investment horizon seeking exposure to this niche market.<\/span>[\/vc_column_text][vc_column_text css=””]<\/p>\n

<\/h2>\n

[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_id=”share_rating”][vc_column_inner width=”1\/2″][vc_column_text css=””]<\/p>\n

Rate this article<\/h6>\n